Long-Term and Interactive Effects of Pay-For-Performance Interventions among Diabetic Nephropathy Patients at the Early Chronic Kidney Disease Stage

Medicine (United States)

Volumn 95, Issue 14, 2016, Pages

  Liao, Pei Ju ^a   Lin, Tzu Yu ^b   Wang, Tzu Ching ^c   Ting, Ming Kuo ^e   Wu, I Wen ^d,f   Huang, Hsin Tsung ^c   Wang, Fu Chung ^c   Chang, Huan Cheng ^g,h   Hsu, Kuang Hung ^b,h  

^a ORIENTAL INSTITUTE OF TECHNOLOGY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c Ministry of Health and Welfare   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e Division of Nephrology   (Taiwan)

^f CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^g Taiwan Landseed Hospital   (Taiwan)

^h CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHARLSON COMORBIDITY INDEX; CHILD; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; FEMALE; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; LIFESTYLE MODIFICATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL HEALTH INSURANCE; OBSERVATIONAL STUDY; PAY FOR PERFORMANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; DIABETIC NEPHROPATHIES; EARLY INTERVENTION; MIDDLE AGED; REIMBURSEMENT; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

AGED; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; MALE; MIDDLE AGED; REIMBURSEMENT, INCENTIVE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84964596833     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003282     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014 Atlanta, GA: US Department of Health and Human Services; 2014
2. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26:77-82.
3. Yang WC, Hwang SJ. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. Nephrol Dial Transplant. 2008;23:3977-3982.
4. Arnal LL, Gutiérrez BC, Izquierdo MC, et al. Prevalence of chronic kidney disease in patients with type 2 diabetes mellitus treated in primary care. Nefrologia. 2010;30:552-556.
5. Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002;137:479-486.
6. United States Renal Data System. 2014 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2014.
7. De Bruin SR, Baan CA, Struijs JN. Pay-for-performance in disease management: a systematic review of the literature. BMC Health Serv Res. 2011;11:272.
8. Eijkenaar F, Emmert M, Scheppach M, et al. Effects of pay for performance in health care: a systematic review of systematic reviews. Health Policy. 2013;110:115-130.
9. Huang J, Yin S, Lin Y, et al. Impact of pay-for-performance on management of diabetes: a systematic review. J Evid Based Med. 2013;6:173-184.
10. Van Herck P, De Smedt D, Annemans L, et al. Systematic review: effects, design choices, and context of pay-for-performance in health care. BMC Health Serv Res. 2010;10:247.
11. Levin-Scherz J, DeVita N, Timbie J. Impact of Pay-for-Performance Contracts and Network Registry on Diabetes and Asthma HEDIS (R)Measures in an Integrated Delivery Network. Med Care Res Rev. 2006;63(1 suppl):14S-28S.
12. Millett C, Netuveli G, Saxena S, et al. Impact of pay for performance on ethnic disparities in intermediate outcomes for diabetes: a longitudinal study. Diabetes Care. 2009;32:404-409.
13. Smith AL. Merging P4P and disease management: how do you know which one is working? J Manag Care Pharm. 2007;13:S7.
14. James W, Snyder JM, Griego J, et al. Quality improvement and cost reduction realized by a purchaser through diabetes disease management. Dis Manag. 2003;6:233-241.
15. Beaulieu ND, Horrigan DR. Putting smart money to work for quality improvement. Health Serv Res. 2005;40:1318-1334.
16. Cupples ME, Byrne MC, Smith SM, et al. Secondary prevention of cardiovascular disease in different primary healthcare systems with and without pay-for-performance. Heart. 2008;94:1594-1600.
17. Howard K, White S, Salkeld G, et al. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis. Value Health. 2010;13:196-208.
18. Karunaratne K, Stevens P, Irving J, et al. The impact of pay for performance on the control of blood pressure in people with chronic kidney disease stage 3-5. Nephrol Dial Transplant. 2013;28:2107-2116.
19. Kondo M, Yamagata K, Hoshi SL, et al. Cost-effectiveness of chronic kidney disease mass screening test in Japan. Clin Exp Nephrol. 2012;16:279-291.
20. Plantinga LC, Fink NE, Jaar BG, et al. Attainment of clinical performance targets and improvement in clinical outcomes and resource use in hemodialysis care: a prospective cohort study. BMC Health Serv Res. 2007;7:5.
21. Stevens PE, de Lusignan S, Farmer CK, et al. Engaging primary care in CKD initiatives: the UK experience. Nephrol Dial Transplant. 2012;27(Suppl 3):iii5-11.
22. Stock S, Drabik A, Buscher G, et al. German diabetes management programs improve quality of care and curb costs. Health Aff. 2010;29:2197-2205.
23. Romano P, Romano L, Roos J, et al. Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075-1079.
24. Chang RE, Lin SP, Aron DC. A pay-for-performance program in Taiwan improved care for some diabetes patients, but doctors may have excluded sicker ones. Health Aff. 2012;31:93-102.
25. Cheng SH, Lee TT, Chen CC. A longitudinal examination of a pay-for-performance program for diabetes care: evidence from a natural experiment. Med Care. 2012;50:109-116.
26. Alexander JA, Hearld LR, Mittler JN, et al. Patient-physician role relationships and patient activation among individuals with chronic illness. Health Ser Res. 2012;47:1201-1223.
27. Fairbrother G, Hanson KL, Friedman S, et al. The impact of physician bonuses, enhanced fees, and feedback on childhood immunization coverage rates. Am J Public Health. 1999;89: 171-175.
28. Liao PJ, Lin ZY, Huang JC, et al. The relationship between type 2 diabetic patients' early medical care-seeking consistency to the same clinician and health care system and their clinical outcomes. Medicine (Baltimore). 2015;94:e554.
29. Stewart M.A. Effective physician-patient communication and health outcomes a review. Can Med Assoc J. 1995;152:1423-1433.
30. Wu IW, Wang SY, Hsu KH, et al. Multidisciplinary predialysis education decreases the incidence of dialysis and reduces mortality-A controlled cohort study based on the NKF/DOQI guidelines. Nephrol Dial Transplant. 2009;24:3426-3433.
31. Roderick P, Armitage A. Renal services for people with diabetes in the UK. Diabetic Med. 2002;19:56-60.
32. Group DCaCTR. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
33. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646-661.
34. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis. 1999;33:1004-1010.
35. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int. 2005;67: 799-812.
36. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-1419.
37. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-Angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-Analysis. Lancet. 2005;366:2026-2033.
38. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569.